Realizing Potential: Taking GDC-0084 Forward in Glioblastoma

Time: 3:30 pm
day: Day Two


  • Identifying a target population: newly-diagnosed versus recurrent patients
  • Addressing the challenges and opportunities in designing a definitive clinical proof-of-concept for GBM
  • Defining a path-to-market for GDC-0084
  • Establishing the commercial prospects for a new drug in GBM